Vivek Subbiah

144PUBLICATIONS
548CO-AUTHORS
NanomedicineMolecular targetsGene and molecular therapyPredictive and prognostic markersCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (144)

|Aug 18, 2026
Safety and efficacy of intratumoral MEDI1191, an IL-12 mRNA lipid nanoparticle, plus intravenous durvalumab in patients with advanced solid tumors: a first-in-human study.

|Aug 11, 2026
ERK1/2 Inhibitor Ulixertinib in Pan-cancer Patients with BRAF Fusions or Non-V600E/K Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1L.

|Jul 11, 2026
Personalized Radionuclide Therapy via Avidin-Biotin Pretargeting: Biodistribution and Dosimetry of 177Lu-DOTA-biotin with AvidinOX™ in Solid Tumors.

|Jun 01, 2026
Tumor-Agnostic Therapies: Translating Scientific Breakthroughs Into Global Implementation.

|Apr 03, 2026
Living Guidelines for Tumor-Agnostic Therapies: A Pathway to Next-Generation Cancer Treatment.

Vivek Subbiah, Thomas K Oliver, Jim Palma

|Mar 26, 2026
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.

Benjamin Besse, Vivek Subbiah, Giuseppe Curigliano

Pageof 24

Frequent Collaborators

15 joint publications

Aung Naing

14 joint publications

Jason Roszik

14 joint publications

David S Hong

13 joint publications

Razelle Kurzrock